| Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide … A Lievre, A Turpin, I Ray-Coquard, K Le Malicot, J Thariat, G Ahle, ... European Journal of Cancer 141, 62-81, 2020 | 143 | 2020 |
| Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial T Conroy, F Castan, A Lopez, A Turpin, MB Abdelghani, AC Wei, E Mitry, ... JAMA oncology 8 (11), 1571-1578, 2022 | 108 | 2022 |
| FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI. 3 for first-line treatment of metastatic pancreatic … L Dahan, JM Phelip, K Le Malicot, N Williet, J Desrame, J Volet, C Petorin, ... Journal of Clinical Oncology 36 (15_suppl), 4000-4000, 2018 | 76 | 2018 |
| Imaging for metastasis in prostate cancer: a review of the literature A Turpin, E Girard, C Baillet, D Pasquier, J Olivier, A Villers, P Puech, ... Frontiers in Oncology 10, 55, 2020 | 66 | 2020 |
| Two cases of immune thrombocytopenia associated with pembrolizumab A Le Roy, E Kempf, F Ackermann, E Routier, C Robert, A Turpin, ... European Journal of Cancer 54, 172-174, 2016 | 53 | 2016 |
| Randomized phase II trial evaluating two sequential treatments in first line of metastatic pancreatic cancer: results of the PANOPTIMOX-PRODIGE 35 trial L Dahan, N Williet, K Le Malicot, JM Phelip, J Desrame, O Bouché, ... Journal of Clinical Oncology 39 (29), 3242-3250, 2021 | 50 | 2021 |
| Bone metastasis: current state of play A Turpin, M Duterque-Coquillaud, MH Vieillard Translational Oncology 13 (2), 308-320, 2020 | 43 | 2020 |
| Professional and psychological impacts of the COVID-19 pandemic on oncology residents: a national survey M Hilmi, A Boilève, A Ducousso, M Michalet, A Turpin, C Neuzillet, ... JCO Global Oncology 6, 1674-1683, 2020 | 42 | 2020 |
| Triplet combination of durvalumab, tremelimumab, and paclitaxel in biliary tract carcinomas: Safety run-in results of the randomized IMMUNOBIL PRODIGE 57 phase II trial A Boilève, M Hilmi, P Gougis, R Cohen, B Rousseau, JF Blanc, ... European Journal of Cancer 143, 55-63, 2021 | 33 | 2021 |
| GCO-002 CACOVID-19 collaborators/investigators. Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the … A Lièvre, A Turpin, I Ray-Coquard, K Le Malicot, J Thariat, G Ahle, ... Eur J Cancer 141, 62-81, 2020 | 27 | 2020 |
| Should all pancreatic surgery be centralized regardless of patients' comorbidity? G Clément, X Lenne, C Laueriere, A Turpin, D Theis, FR Pruvot, S Truant HPB 22 (7), 1057-1066, 2020 | 23 | 2020 |
| Hereditary predisposition to cancers of the digestive tract, breast, gynecological and gonadal: Focus on the Peutz-Jeghers A Turpin, S Cattan, J Leclerc, A Wacrenier, S Manouvrier-Hanu, ... Bulletin du Cancer 101 (9), 813-822, 2014 | 23 | 2014 |
| Biomarkers of response to etoposide-platinum chemotherapy in patients with grade 3 neuroendocrine neoplasms C Lacombe, O De Rycke, A Couvelard, A Turpin, A Cazes, O Hentic, ... Cancers 13 (4), 643, 2021 | 20 | 2021 |
| Adjuvant pancreatic cancer management: towards new perspectives in 2021 A Turpin, M El Amrani, JB Bachet, D Pietrasz, L Schwarz, P Hammel Cancers 12 (12), 3866, 2020 | 20 | 2020 |
| Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies A Turpin, C Neuzillet, E Colle, N Dusetti, R Nicolle, J Cros, L De Mestier, ... Therapeutic Advances in Medical Oncology 14, 17588359221118019, 2022 | 19 | 2022 |
| Impact of the COVID-19 pandemic on disease stage and treatment for patients with pancreatic adenocarcinoma: a French comprehensive multicentre ambispective observational cohort … M Brugel, L Letrillart, C Evrard, A Thierry, D Tougeron, M El Amrani, ... European Journal of Cancer 166, 8-20, 2022 | 19 | 2022 |
| LBA57 Unicancer PRODIGE 24/CCTG PA6 trial: updated results of a multicenter international randomized phase III trial of adjuvant mFOLFIRINOX (mFFX) versus gemcitabine (gem) in … T Conroy, P Hammel, A Turpin, C Belletier, A Wei, E Mitry, A Lopez, ... Annals of Oncology 32, S1334, 2021 | 17 | 2021 |
| Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: an AGEO European Cohort J Taïeb, L Sayah, K Heinrich, V Kunzmann, A Boileve, G Cirkel, S Lonardi, ... European Journal of Cancer 188, 90-97, 2023 | 15 | 2023 |
| Proton pump inhibitors and cancer: current state of play M Bridoux, N Simon, A Turpin Frontiers in Pharmacology 13, 798272, 2022 | 15 | 2022 |
| Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized … T Conroy, F Castan, A Lopez, A Turpin, M Ben Abdelghani, AC Wei, ... JAMA Oncol 8 (11), 1571-1578, 2022 | 14 | 2022 |
